[P53, ARF and P16: the last defence against reprogrammation].
Institut de recherche en biothérapie, IRB, Inserm U847, Equipe développement embryonnaire précoce et cellules souches, Hôpital Saint-Eloi, 80, avenue A. Fliche, 34295 Montpellier, France.
Maryline
M
Dijon-Grinand
John
J
De Vos
D020823:ADP-Ribosylation Factor 1 / Q000502:physiology*; D000818:Animals; D002454:Cell Differentiation; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000502:physiology*; D006801:Humans; D051379:Mice; D039904:Pluripotent Stem Cells / Q000166:cytology / Q000502:physiology*; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics / Q000502:physiology*
D019941:Cyclin-Dependent Kinase Inhibitor p16; D016159:Tumor Suppressor Protein p53; D020823:ADP-Ribosylation Factor 1